Purpose: To evaluate the treatment of selected patients with uveal melanoma with endoresection and adjuvant ruthenium brachytherapy. Methods: Thirty-five patients with uveal melanoma not suitable for ruthenium plaque monotherapy were treated with endoresection and adjuvant ruthenium brachytherapy between January 2001 and October 2013. Recurrence-free survival, globe retention, course of visual acuity (VA), occurrence of therapy-related complications and metastasis-free and overall survival were analysed retrospectively. Results: Eight patients (22.9%) had a tumour recurrence after a median followup of 49.5 months (range: 21-134 months). Enucleation was necessary in eight patients. Thirty-two patients (91%) had a loss of VA with a median loss of nine lines (range: 0 to À39 lines); VA was stable in three patients and no patients had a gain in VA. Four patients (11.4%) developed radiation retinopathy. Metastases were detected in seven patients (20.0%) during follow-up. The occurrence of metastasis was significantly associated with monosomy 3 (p < 0.0001). Twenty-four patients (68.6%) were alive at the end of follow-up. Five patients (14.3%) died because of uveal melanoma (UM) metastasis. Conclusions: Endoresection with adjuvant ruthenium brachytherapy is an option for selected patients with UM who cannot be treated with brachytherapy as monotherapy. About two-thirds of eyes can be retained long term without recurrences. Visual acuity cannot be maintained in most cases, and may even decrease considerably. Radiation complications are comparatively rare and not a significant problem.
Introduction
Uveal melanoma (UM) is the most common malignant intraocular tumour in adults and a sight-and life-threatening disease. It is assumed that in most cases treatment of the primary tumour in the eye will not influence patient survival because early tumour cell dissemination with the establishment of micrometastases will have already occurred at diagnosis (Eskelin et al. 2000; Singh 2001; Singh et al. 2004) . Uveal melanoma (UM) with a tumour thickness <6 mm can be successfully administered ruthenium brachytherapy, achieving high tumour control rates (Lommatzsch 1986 ). Juxtapapillary UM and UM with a tumour thickness >6 mm remain a treatment challenge in terms of tumour control and the occurrence of complications threatening visual acuity and globe salvage. The use of Iodine125 plaques or teletherapy as monotherapy or with additional surgery should be considered in such cases. Especially proton beam radiotherapy is associated with a high percentage of radiation retinopathy and opticopathy (H€ ocht et al. 2004; Dendale et al. 2006) or rubeotic glaucoma (Dendale et al. 2006; Willerding et al. 2016) . We thus decided to combine tumour resection with adjuvant brachytherapy as an alternative to enucleation. The rationale for combining surgical removal of the tumour with radiotherapy is that a high percentage of UM have already invaded the sclera (Collaborative Ocular Melanoma Study Group 1998; Damato et al. 2000; Dennis 2001 ). These cells cannot be completely destroyed by surgery; however, they may be the reason source for later tumour recurrences. In addition, most recurrences after tumour resection are found histopathologically at the site of the original malignancy or at the edge of the site of surgical resection, suggesting that these recurrences are the result of residual tumour not seen at the time of resection (Hadden et al. 2004) . But recurrences have also been found in distant sites and even extraocularly, after endoresection without adjuvant/neoadjuvant treatments (Mittica et al. 2003) . On the other hand, radiation of a large UM often results in serious radiation complications such as radiation retinopathy, neovascular glaucoma or even a toxic tumour syndrome that is provoked by the release of toxic substances by the necrotic tumour mass, giving rise to extensive inflammatory intraocular alterations with persistent exudative retinal detachment necessitating enucleation of the eye.
Patients and Methods

Data acquisition
Patient charts were reviewed for the diagnosis of UM treated between January 2000 and November 2013. Patients were included in the study if (1) they had a diagnosis of UM, (2) were treated with combined endoresection and adjuvant ruthenium brachytherapy, and (3) had been followed-up for at least 12 months. For this type of study no formal consent was required.
The following data were recorded: patient variable characteristics were patient age, patient gender, treated eye and visual acuity (VA) in logMAR. Tumour variable characteristics were tumour location, tumour distance to optic disc and macula, ciliary body involvement, extraocular growth, tumour thickness, largest basal diameter, tumour, node, metastasis (TNM) size and TNM stage according to the 7th edition of the TNM classification of malignant tumours, histological cell type and monosomy 3 status explored by multiplex ligation-dependent probe amplification (Damato et al. 2010) . Treatment variable characteristics were treatment date, treatment complications with date of first occurrence, tumour recurrence with date of recurrence, occurrence of metastasis with date of first diagnosis and metastasisrelated death with date.
Visual acuity was further grouped as follows: <0.2 logMAR (n = 10), 0.2-0.4 logMAR (n = 10), 0.5-1.0 logMAR (n = 7) and >1.0 logMAR (n = 8).
Tumour location was categorized as follows: anterior location: in the ciliary body (n = 0); anterior and peripheral: anterior to the equator with ciliary body involvement (n = 1); peripheral:
anterior to the equator (n = 5); peripheral and posterior: from anterior to the equator to the posterior pole (n = 19); posterior: posterior to the equator involving the posterior pole near the optic disc and the macula (n = 10).
Tumour thickness was measured echographically using A-mode scans from the retinal echo at the tumour apex to the scleral echo at the tumour base. The largest basal diameter (LBD) was measured using B-mode scans.
Three continuous variables (patient age, tumour thickness and LBD) were grouped in categories to allow analysis of subgroups: age categories were 41-50 years (n = 3), 51-60 years (n = 11), 61-70 years (n = 13), 71-80 years (n = 6) and 81-90 years (n = 2); tumour thickness categories were 0-6.0 mm (n = 8), 6.1-9.0 mm (n = 20), 9.1-15.0 mm (n = 7) and >15.0 mm (n = 0) and LBD categories were 0-12.0 mm (n = 14), 12.1-18.0 mm (n = 21) and >18.0 mm (n = 0).
Tumour cell type was determined histologically according to the modified Callender classification and categorized as spindle cell, epithelioid cell or mixed cell type (McLean et al. 1983 ).
Treatment procedure
Phacoemulsification with intraocular lens implantation was carried out as a standard procedure at the beginning of treatment to achieve a better insight and to allow the surgeon to work with the instruments in the far periphery. A 20-gauge pars plana vitrectomy was performed in all cases. Then, a retinotomy anterior to the UM was carried out, the retina was turned down using perfluorocarbon liquid and the tumour was surrounded by endolaser photocoagulation using a Neodymium: Yttrium-alumnium-garnet (Nd:YAG) frequency-doubled 532-nm green diode laser. Endoresection was preferentially performed by completely shelling out the tumour and removing it as a whole through an enlarged sclerotomy in 29 cases with the aim of preventing tumour cell dissemination from surgical manipulation, or with the cutter where this was not possible in six cases. After removing the tumour, laser photocoagulation was executed in the scleral bed with the aim of destroying residual tumour cells. At the end of the procedure the retina was reattached by perfluorocarbon liquid exchange and fixed with endolaser photocoagulation. The eye was filled with silicone oil at the end of the procedure. Endoresection was combined with transscleral extraction of the anterior part of the tumour in two patients with ciliary body involvement by preparing a lamellar scleral flap. At the end of surgery a ruthenium 106 plaque (Eckert & Ziegler BEBIG, Berlin, Germany) matching the size of the tumour base with a safety margin of ≥ 2 mm was sutured onto the sclera covering the whole resection area with the aim of destroying residual tumour cells in the scleral bed or at the resection edges. In five patients the ruthenium plaque was sutured onto the sclera after a median of 11 months (range: 6-13 months) after the endoresection because the applicators had not been available at the time of surgery. Exposure time was calculated assuming a scleral thickness of 1 mm and aiming at a dose of 100 Gy at 3 mm depth, resulting in a mean apex dose of 104.9 Gy (range: 90.7-131.6 Gy) and a mean scleral dose of 320.4 Gy (range: 238.9-412.9 Gy).
Statistical analysis
SPSS software version 22 (IBM Deutschland GmbH, Ehningen, Germany) was used for statistical analysis. Patient, tumour and treatment characteristics including recurrences, enucleations, metastases and deaths were reported as numbers and percentages (categorical data), medians with ranges (numerical data) or means with standard deviations (SD) (continuous data). Survival data were calculated by KaplanMeier, p values were derived from log rank tests. All data should be regarded as explorative. No level of significance was specified in advance, and the pvalues are merely descriptive.
Results
Patient and tumour characteristics
In total, 35 patients with UM were treated with combined tumour resection and adjuvant ruthenium brachytherapy between January 2001 and October 2013. Twenty patients (57.1%) were men, and 15 (42.9%) were women. Twenty right eyes (57.1%) and 15 left eyes (42.9%) were treated. Twenty-one patients (60%) were above 60 years old (median: 62 years, range: 46-81 years). Followup ranged between 12 and 154 months (mean: 65.7 months, SD 44.0 months, median: 47 months).
Tumour characteristics are summarized in Table 1 .
Local tumour control and globe salvage Eight patients (22.9%) suffered from local tumour recurrence after a median of 49.5 months (range: 21.0-134.0 months, mean: 59.1 months, SD 36.53 months). In three patients the recurrence appeared at the edge of the resection area, in three patients the recurrence appeared distant to the surgical choroidal coloboma, in one patient recurrences occurred both at the edge and distant to the surgical coloboma and in one case it was not documented. In two of those cases a diffuse dissemination of the tumour cells was seen in the eye. In two patients the recurrence was accompanied by an extraocular growth. Seven patients (20.0%) had one tumour recurrence and one patient (2.9%) had three tumour recurrences. In six patients (17.1%) the tumour recurrence was salvaged directly by enucleation of the eye. In one patient with a distinct extraocular growth exenteration of the orbit was mandatory. One patient had transpupillary thermotherapy of the first recurrence followed by cryodestruction of the second recurrence resulting in enucleation in the end. (Fig. 1B) . The appearance of a recurrence was significantly associated with enucleation (p < 0.0001).
One recurrence occurred in the group of patients with tumours resected with the cutter and two recurrences appeared in the group of patients with later adjuvant ruthenium application.
Visual acuity
Thirty-two patients suffered from a loss of VA (median: À9, range: 0 to À39 lines). Three patients had a stable VA. No patient had any gain in VA. The course of VA during the study period is summarized in Table 2 .
Treatment complications
Radiation complications
Four patients developed radiation retinopathy (11.4%). Radiation retinopathy-free survival was 97.1% (SE: 0.028) 1 year, 90.9% (SE: 0.05) 2 years and 87.5% (SE: 0.059) 3, 5 and 10 years posttreatment (Fig. 1C) . The median time interval until the occurrence of radiation retinopathy was 18.5 months (range: 7-28 months). The appearance of radiation retinopathy was associated with TNM size and TNM stage (p < 0.0001). Two patients developed radiation-related macular oedema (5.7%).
Surgery-and/or radiation-related complications
In three patients (8.6%), choroidal neovascularization (CNV) was diagnosed via fluorescein angiography. Two CNVs appeared at the edge of the surgical coloboma and one CNV in the macula distant to the resection area. A pale optic disc (opticopathy) was seen in 11 eyes (31.4%). The appearance of opticopathy was significantly associated with TNM size and stage (p = 0.009). Opticopathy-free survival was 88.5% (SE: 0.054) 1 year, 82.3% (SE: 0.066) 2 years, 72.0% (SE: 0.08) 3 years, 68.0% (SE: 0.085) 5 years and 61.2% (SE: 0.1) 10 years posttreatment. The median time interval until the occurrence of opticopathy was 24 months (range: 6-65 months) and was significantly associated with the TNM size and stage (p = 0.009).
Surgery-related complications Early complications (<3 months postoperatively). In two patients some of the silicone oil had to be removed because of eye pressures >50 mmHg during the first postoperative days.
Late complications (>3 months postoperatively). Three patients (8.6%) had corneal decompensation because of silicone oil or haemorrhage in the anterior chamber postoperatively. Two patients developed epiretinal membrane formation, four patients had retinal detachment because of proliferative vitreoretinopathy, one patient had macular hole formation, one patient had persistent corneal erosion with the need of an amnion membrane transplantation and two patients developed corneal band keratopathy. Two patients ended up with persistent hypotony of the eye (7 mmHg and 8 mmHg, respectively).
Occurrence of metastasis and death
Seven patients (20.0%) developed metastases during follow-up. The median time to the occurrence of metastasis was 66 months (range: 30-102 months). Metastasis-free survival was 100% 1 year posttreatment, 92.0% (SE: 0.055) 5 years posttreatment and 57.9% (SE: 0.129) 10 years after treatment (Fig. 1D) . The occurrence of metastasis was significantly associated with chromosome 3 status (p < 0.0001). The appearance of a recurrence was not associated with metastasis (p = 0.781). No difference in the occurrence of metastasis was seen whether the tumour was resected as a whole or with the cutter (p = 0.947) or whether the ruthenium applicator was sutured onto the sclera at the end of the surgery or several months later (p = 0.555).
Twenty-four (68.6%) patients were alive at the end of the follow-up period, seven patients (20.0%) died and four patients (11.4%) were lost to followup. Death was related to metastasis in five of the deceased patients (71.4%), in one patient the cause of death was not known and one patient died of another tumour-unrelated cause.
Overall survival was 100% 1 year post-treatment, 86.0% (SE: 0.077) 5 years post-treatment and 65.5% (SE: 0.119) 10 years after treatment. Median survival time was 72 months (range: 17-110 months). The median interval between detection of metastasis and death was 10 months (range: 3-15 months).
Metastasis and chromosome 3 status were significantly related to reduced overall survival (p = 0.004). The occurrence of a recurrence (p = 0.258) did not seem to influence overall survival. Peyman & Cohen (1986) were the first to perform tumour resection ab interno for UM in 1986 with the particular aim of treating UM located 1-2 disc diameters from the optic disc. Later, Lee et al. (1993) and Damato et al. (1998) reported their results using the same technique. Damato et al. (1998) were the first to use the term endoresection. Adjuvant or neoadjuvant radiotherapy was not used or not routinely used in these studies. In this study all patients received adjunctive radiotherapy after endoresection because of the fear of tumour cells remaining in the scleral bed or the resection edges leading to tumour recurrences. Therefore, the local control should have been higher in comparison to treatment results without radiotherapy. The use of an adjunctive ruthenium plaque has been suggested as a tool to prevent tumour recurrences in transscleral resection (Damato et al. 1996; Damato 1997; Bechrakis et al. 2010 ). Eight patients (22.9%) in the present cohort suffered from tumour recurrence. The 1-, 2-, 3-, 4-, 5-and 10-year probability of being free of a tumour recurrence was 100%, 96.9%, 93.5%, 83.7%, 77.3% and 62.9%, respectively. Kertes et al. (1998) had only one recurrence (3.1%) in 32 patients with posterior UM treated by internal resection without additional radiotherapy. However, in that study the tumours were smaller and all posteriorly located. GarciaArumi et al. (2001) had no recurrences in their cohort of 25 patients with high posterior choroidal melanomas treated by endoresection. Adjunctive ruthenium brachytherapy was only performed in cases with residual tumour with 80 Gy delivered to a depth of 3 mm. The UM treated in this study was similar to LBD, however, the mean follow-up was only 31 months in comparison to our study with a mean follow-up of 65.7 months. Schilling et al. (2006) presented their results of 46 patients with UM treated by endoresection after pretreatment with singledose stereotactic convergence irradiation using the Leksell Gamma-Knife. After a short median follow-up of 13 months no recurrences were detected. In a study published by our group reporting about 18 patients with endoresection after neoadjuvant singledose stereotactic radiotherapy with the linear accelerator, no recurrences occurred after a median follow-up of 33.37 months (Suesskind et al. 2013 ). In the study performed by Karkhaneh et al. (2007) , 20 patients with UM underwent endoresection without adjuvant radiotherapy. After a mean follow-up of 89.55 months two recurrences (10%) occurred, one at the margin of the surgical coloboma and one at a distant site. Bechrakis et al. (2009) treated 142 patients with primary proton beam irradiation followed by endoresection of the UM. The 5-year probability of tumour control was 98%, the mean follow-up was 30 months. The patient cohort was not characterized in detail, however, the tumour thickness was >7.0 mm in all cases and tumours were located posteriorly or peripherally without ciliary body involvement. Konstantinidis et al. (2014) reported their results of 71 posterior UM patients who underwent endoresection without adjuvant radiation. Local tumour recurrence developed in two patients (3%) at the margin of the coloboma in both cases. The median follow-up was 49 months, however, tumours were consistently smaller compared to the present cohort. In 2015 Garcia-Arumi et al. published their extended follow-up results of 41 patients with high posterior UM treated by endoresection, of which 21 cases underwent adjuvant brachytherapy. The mean follow-up time of the study was 102.5 months. Five patients (12.2%) without additional brachytherapy suffered from local tumour recurrence. The highest percentage of recurrences was seen in our cohort. However, the follow-up in our study was longer than in most of the other mentioned publications and the mean LBD of the uveal melanomas treated in our series was larger compared to the other series. For an overview please refer to Table 3 . It is possible that the adjuvant ruthenium brachytherapy was not successful in reducing tumour recurrences in our patient cohort in comparison with the other published studies. Because three of the recurrences appeared at the edge of the resection area it is possible that the ruthenium plaques were not large enough to cover the whole residual tumour. Damato (2012) has observed a decrease in local tumour recurrences after transscleral resection with the introduction of adjunctive brachytherapy using 25-mm ruthenium plaques. It might also be that surgery resulted in choroidal metastasis of uveal melanoma that would explain the distant recurrences in these cases. Eight eyes (22.9%) were enucleated because of recurrences in these cases. Fortunately, no enucleation had to be performed because of surgery-related complications. In the other published reports about endoresection, the enucleation rates were lower than in our study (Table 3) . This result follows the number of recurrences in our series that are less in the other published reports (Kertes et al. 1998; GarciaArumi et al. 2001 GarciaArumi et al. , 2015 Schilling et al. 2006; Karkhaneh et al. 2007; Bechrakis et al. 2009; Konstantinidis et al. 2014) .
Discussion
Visual acuity may decrease after therapy and in the years following treatment. Only four patients retained their initial visual acuity; 68.6% of the patients had a VA > 1.0 logMAR at the last visit. Kertes et al. (1998) reported that 68.8% of the patients had a VA > 1.0logMAR (<6/60), the mean postoperative VA reported by Garcia-Arumi et al. (2001) was 0.7log-MAR (20/100) and the median postoperative VA in the series studied by Schilling et al. (2006) was 0.6logMAR (0.25). Postoperative VA ranged from no light perception to 0.2logMAR (20/ 30) in Karkhaneh et al. (2007) . Sixtynine per cent of the patients studied by Konstantinidis et al. (2014) had a final VA ≥ 0.7logMAR (≤6/30), and in the extended report published by GarciaArumi et al. (2015) the mean final bestcorrected VA was 2.0logMAR (20/ 1625). In the study of Suesskind et al. (2013) , 17/18 patients had a decrease in VA. In summary, VA decreased obviously and concordantly in all published series about endoresection probably because most tumours were located near the optic disc and macula.
Radiation complications are not a serious problem after the described treatment procedure. The appearance of radiation retinopathy was associated with TNM size and stage. This seems logical because larger UMs with larger LBDs were treated with larger amounts of radiation. Only four patients developed radiation retinopathy and two patients a macular oedema treated by laser coagulation and/or intravitreal anti-VEGF therapy.
Metastasis was detected in seven patients (20%) during the study period and was significantly associated with monosomy 3. Overall survival was also significantly associated with the occurrence of metastasis and monosomy 3. The chromosome 3 status was not analysed in the other published endoresection studies. The occurrence of a recurrence did not seem to influence metastasis or overall survival within the limited follow-up of this study. It thus seems that the higher rate of recurrences in our series did not influence the appearance of metastases, however, this has to be reviewed within a longer follow-up because other studies documented that local tumour recurrence was associated with an increased risk of metastasis (Jampol et al. 2002 , Caujolle et al. 2013 Ophthalmic Oncology Task Force 2016) .
In conclusion, endoresection with adjuvant ruthenium brachytherapy is an option for selected patients with UM who cannot be treated with brachytherapy as monotherapy. About two-thirds of eyes can be retained long term without recurrences. Visual acuity cannot be maintained in most cases, and may even decrease considerably. Radiation complications are rare and not a significant problem. Regarding the high recurrence rates we have to think about using larger ruthenium plaques. Considering the low recurrence rates in the studies with neoadjuvant radiation before tumour resection (Bechrakis et al. 2009; Suesskind et al. 2013 ) in comparison to this study we have to reflect on changing to the neoadjuvant radiotherapy concept. 
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